November 24, 2024

• 

[THE INVESTOR] YD Global Life Science said on Aug. 21 it has received approval from the US Food and Drug Administration to initiate phase 2a clinical trials of YD-312, its drug candidate to treat diabetic retinopathy.

“We are pleased to win clinical study approval for the diabetic retinopathy therapy following the green light for phase 2a clinical trials of YD Global Life Science’s diabetic macular edema treatment by the FDA in April,” CEO Lee Jin-woo said.

Diabetic retinopathy is the most common eye disease that affects millions of people with diabetes and is a leading cause for vision loss.

The drug candidate is designed to inhibit retinal vascular permeability that causes vision impairment, according to the firm.

The CEO said the company has laid the groundwork to enter global markets worth approximately 12.5 trillion won (US$11.16 billion) by completing patent filing in the US, Japan and Canada.

By Park Han-na (hnpark@heraldcorp.com)